华特达因(000915) - 2017 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2017 was ¥448,311,308.58, representing a 35.33% increase compared to ¥331,268,746.34 in the same period last year[4] - Net profit attributable to shareholders for Q1 2017 was ¥86,531,123.69, an increase of 85.70% from ¥46,596,827.33 in the previous year[4] - The basic earnings per share for Q1 2017 was ¥0.48, up 84.62% from ¥0.26 in the same period last year[4] - The company's operating revenue for Q1 2017 was CNY 448,311,308.58, representing a 35.33% increase compared to CNY 331,268,746.34 in Q1 2016, primarily due to growth in pharmaceutical product sales[14] - Net profit attributable to shareholders of the parent company increased by 85.70% to CNY 86,531,123.69 from CNY 46,596,827.33, driven by higher net profits from pharmaceutical products[14] Cash Flow and Expenses - The net cash flow from operating activities decreased significantly by 85.80%, amounting to ¥8,464,653.19 compared to ¥59,627,880.74 in the previous year[4] - The company reported non-operating income of ¥141,018.62 during the reporting period[6] - The company's financial expenses decreased by 93.49% to CNY 578,185.94 from CNY 8,883,811.50, mainly due to a reduction in cash discounts[14] - The company reported a 98.06% increase in income tax expenses, amounting to CNY 28,091,174.88, attributed to an increase in total profit for the period[14] - The company’s management expenses rose by 34.16% to CNY 30,962,783.54, primarily due to increased R&D expenditures[14] - The company’s investment income decreased by 86.70% to CNY 85,461.72 from CNY 642,449.32, mainly due to reduced investment income from bank wealth management products[14] - The company’s cash paid to employees increased by 60.50% to CNY 93,157,645.70, reflecting higher employee compensation[14] - The company’s cash paid for various taxes increased by 107.15% to CNY 102,848,212.27, driven by growth in operating revenue and performance[14] - The company’s cash received from investment decreased by 38.33% to CNY 80,050,000.00, primarily due to a reduction in the maturity of bank wealth management products[14] Assets and Shareholder Information - Total assets at the end of Q1 2017 were ¥2,494,254,925.66, a slight increase of 0.49% from ¥2,482,210,141.83 at the end of the previous year[4] - Net assets attributable to shareholders increased by 6.70% to ¥1,370,064,382.78 from ¥1,283,989,079.96 at the end of the previous year[4] - The weighted average return on equity rose to 6.52%, an increase of 2.38 percentage points from 4.14% in the previous year[4] - The total number of ordinary shareholders at the end of the reporting period was 14,818[8] - The largest shareholder, Shandong University Industry Group Co., Ltd., holds 20.72% of the shares, totaling 37,341,800 shares[8] Regulatory and Certification - The company’s subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., received a GMP certificate from the Australian Therapeutic Goods Administration during the reporting period[15]